RESEARCH TRIANGLE PARK, N.C. – August 3, 2011 – Quintiles announced the appointment of Jeffrey A. Spaeder, M.D., as its Chief Medical and Scientific Officer. He succeeds Dr. Oren Cohen who now leads Quintiles’ Phase I clinical research business.
In this role, Dr. Spaeder will serve as Quintiles' lead medical expert, representing the company's position on a wide variety of governance, ethical and scientific issues. As Chief Medical and Scientific Officer, Dr. Spaeder will provide leadership in the ethical conduct of studies. He will chair Quintiles’ Drug Safety Committee and serve as vice-chair of Quintiles’ Council on Research Ethics. Additionally, Spaeder will provide guidance on strategic scientific initiatives.
"We are delighted to have a physician and cardiologist of Jeff Spaeder’s stature join Quintiles as our Chief Medical and Scientific Officer,” said Dr. Derek Winstanly, Chief Customer and Governance Officer. “He will be the public face and voice of Quintiles, acting as an industry thought leader, and a champion of ethical conduct and behavior.
“Jeff will collaborate with Quintiles’ global operations and innovation colleagues to ensure the achievement of our strategic goals,” Winstanly said. “In addition to his medical, clinical development, and business background, Jeff also holds a degree in engineering, bringing a unique combination of talents to Quintiles.”
Prior to joining Quintiles, Dr. Spaeder served in several increasingly senior roles within the biopharmaceutical industry. Most recently, he was executive director of global medical affairs for Takeda Pharmaceuticals International. There, he developed global medical affairs strategy for the cardio-metabolic and diabetes franchises.
Previously, Dr. Spaeder served as director of alliance management with Abbott Laboratories where he managed clinical oncology research collaboration with a biotechnology partner. Previous responsibilities at Abbott included a variety of roles in phase 1-3 clinical development, and life cycle management in the neuroscience, renal, and cardiovascular therapeutic areas.
Before his work with Abbott and Takeda, Dr. Spaeder was an instructor in cardiology at the Johns Hopkins University School of Medicine where he conducted research in personalized medicine and novel uses of telemedicine. He also holds multiple U.S. patents for medical applications of advanced technologies, telemedicine and information systems.
Dr. Spaeder is a graduate of the Pennsylvania State University and the Johns Hopkins University School of Medicine. He also holds a master of business administration (MBA) degree from Northwestern University with a concentration in finance. He is a fellow of the American College of Cardiology and a diplomate in cardiovascular disease with the American Board of Internal Medicine.
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.